Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6631050 | 0.81 | CYP2C9 (0.34) | — | |
| SCHEMBL19345919 | 0.77 | CA1 (0.44) | — | |
| SCHEMBL23496358 | 0.76 | CTSC (0.33) | — | |
| SCHEMBL4148404 | 0.76 | CTSC (0.35) | GRIK1GRIK2 | |
| SCHEMBL19746504 | 0.74 | CYP2D6 (0.39) | — | |
| SCHEMBL19745117 | 0.73 | GRIK1 (0.34) | GRIK1GRIK2 | |
| SCHEMBL4813029 | 0.70 | CTSS (0.38) | — | |
| SCHEMBL6402816 | 0.70 | CTSS (0.38) | — | |
| SCHEMBL4813012 | 0.70 | CTSS (0.38) | — | |
| SCHEMBL6402824 | 0.70 | CTSS (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3472130-B1 | ALIPHATIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2022-02-16 | — | — | EP | disclosed |
| US-10730832-B2 | Aliphatic prolinamide derivatives | Orion Ophthalmology LLC (US) | 2020-08-04 | — | — | US | disclosed |
| US-20190330146-A1 | ALIPHATIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2019-10-31 | — | — | US | disclosed |
| EP-3472130-A1 | ALIPHATIC PROLINAMIDE DERIVATIVES | ORION OPTHALMOLOGY LLC (US) | 2019-04-24 | — | — | EP | disclosed |
| WO-2017222917-A1 | ALIPHATIC PROLINAMIDE DERIVATIVES | INCEPTION 4, INC. (US) | 2017-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10730832-B2 | Aliphatic prolinamide derivatives | HTRA1, ALDH1A2, PREP | GRIK1 2655/4885GRIK2 3695/4885 |
| US-20190330146-A1 | ALIPHATIC PROLINAMIDE DERIVATIVES | HTRA1, ALDH1A2, PREP | GRIK1 2655/4885GRIK2 3695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.